Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Total monthly reach
Estimated from 9 chart positions in 9 markets.
By chart position
- 🇨🇦CA · Life Sciences#1455K to 30K
- 🇩🇪DE · Life Sciences#1635K to 30K
- 🇮🇳IN · Life Sciences#8110K to 30K
- 🇸🇪SE · Life Sciences#1801K to 10K
- 🇭🇺HU · Life Sciences#513K to 10K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
17K to 72K🎙 Weekly cadence·221 episodes·Last published 2w ago - Monthly Reach
Unique listeners across all episodes (30 days)
34K to 143K🇨🇦21%🇩🇪21%🇮🇳21%+6 more - Active Followers
Loyal subscribers who consistently listen
10K to 43K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
Recent episodes
The GPCR Antibody Nobody Could Validate - GeneTex - Alexander Ball & Chia-Yi Lin
Jun 17, 2026
Unknown duration
Three Adhesion GPCRs and No Rulebook - Beatriz Blanco
May 27, 2026
Unknown duration
Chimeric GPCRs: Why the Easy Designs Fail — Charlotte Crauwels
May 13, 2026
Unknown duration
The Beta-2 Agonist That Doesn't Stop Working — Tore Bengtsson
May 6, 2026
Unknown duration
One Molecule, Two Opioid Receptors - Joseph Kim
Apr 29, 2026
Unknown duration
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Description | Length | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 6/17/26 |  The GPCR Antibody Nobody Could Validate - GeneTex - Alexander Ball & Chia-Yi Lin | Most GPCR antibody failures are silent. The signal looks clean, the band is there, the experiment moves forward - until someone runs a knockout control and the signal is still there. Lin and Ball have spent years building reagents for exactly this problem, and this conversation gets into the details of what reliable GPCR antibody characterization actually requires.Chia-Yi Lin and Alexander Ball are scientists-turned-industry professionals at GeneTex, a company that has shifted its entire new antibody production to recombinant monoclonal technology since 2019. In this conversation, they trace the arc from GeneTex's founding by cancer biology researchers in 1990s Texas to its current position as a growing source of characterized GPCR research reagents. The discussion covers why GPCR targets are especially difficult immunogen design problems, what five-pillar antibody characterization looks like for receptors like LGR5 and the chemokine receptor family, and why the word "characterized" may be more scientifically honest than "validated" when describing what an antibody data sheet actually tells you. Ball's path from medicine to the bench to industry - and Lin's from stem cell biology to leading international operations at GeneTex - brings a rare dual perspective to a problem that most researchers only see from one side.Key topics covered:Why GPCR family homology - including the 75% sequence identity between CXCR1 and CXCR2 - makes immunogen selection the critical upstream decision in antibody development, often determining success or failure before a single experiment is runWhat five-pillar characterization looks like in practice: KO and KD validation, comparable antibody testing, cell fractionation, tissue orthogonal testing, and GPCR virion arrays from CDI LabsHow recombinant monoclonal antibodies solve the batch variability problem that polyclonal production cannot - and why a sequence defined in a plasmid changes reproducibility for the entire fieldThe LGR5 story: how one leucine-rich repeat GPCR critical to intestinal stem cell biology became GeneTex's defining early challenge - and why Ball's company president went pale when the target came upWhy Ball and Lin encourage researchers to contact the company directly before purchasing, what questions to ask, and how a free GPCR antibody sample program is actively connecting the community with reagents that need real-system testingDr. GPCR Links and ResourcesDr. GPCR Ecosystem: https://www.ecosystem.drgpcr.com/Membership and Pricing: https://www.ecosystem.drgpcr.com/university-pricingWeekly News: https://www.ecosystem.drgpcr.com/gpcr-weekly-news | — | ||||||
| 5/27/26 |  Three Adhesion GPCRs and No Rulebook - Beatriz Blanco | Most receptors come with a history. Remulate came with a name — and almost nothing else. Dr. Beatriz Redondo, group leader at the University of Leipzig, has spent the last nine years building the first systematic characterization of adhesion GPCRs in Drosophila, including three receptors so new they were named after condiments. What she's constructing isn't just a receptor profile — it's a method for doing discovery when the tools don't exist yet.Dr. Redondo uses CRISPR, genetic tagging, and in vivo behavioral assays to place and characterize adhesion GPCRs in a system where generations turn over in weeks. Her work on remulate — a neuronal adhesion GPCR with a human ortholog linked to vascular malformations and blood-brain barrier dysfunction — is among the first of its kind in any organism.Key takeaways:Why Drosophila remains a productive system for receptor discovery in the genomics eraHow CRISPR and epitope tagging replace antibody-based tools for understudied GPCRsWhat nocifensive behavior in larvae reveals about remulate's neuronal functionHow basic science in an insect model connects to vertebrate disease biologyWhat it looks like to characterize a receptor from scratch — with no prior literature to build onDr. GPCR University — live and on-demand courses for scientists working on real discovery problems: https://www.ecosystem.drgpcr.com/gpcr-universityThis episode is supported by Eurofins DiscoverX and GeneTex: https://www.ecosystem.drgpcr.com/eurofins-discoverx | https://www.ecosystem.drgpcr.com/genetex | — | ||||||
| 5/13/26 |  Chimeric GPCRs: Why the Easy Designs Fail — Charlotte Crauwels | What if two nearly identical GPCRs make a worse chimera than two receptors from completely different classes? Charlotte Crauwels is building computational tools to find out why — and to predict which designs will work before they reach the bench.Crauwels develops in silico pipelines for chimeric GPCR design at the Free University of Brussels. Her work sits at the interface of computational prediction and experimental validation, addressing a problem the field has struggled with for decades: chimeric constructs are powerful but unpredictable, and the data surrounding them is scattered, inconsistently named, and poorly annotated. After spending over a year collecting and standardizing published chimeric GPCR data, she built GPCR ChimeraDB — one of the first public databases dedicated to these constructs.Key takeaways:How chimeric GPCRs can deorphanize receptors and reveal signaling pathways that were previously inaccessibleWhy computational ranking of chimeric candidates replaces trial-and-error in the labWhat inconsistent nomenclature and missing annotations cost the field — and how better data sharing changes the gameWhy the feedback loop between computational and experimental scientists is non-negotiable for GPCR researchDr. GPCR Links & ResourcesDr. GPCR Ecosystem: https://www.ecosystem.drgpcr.com/Membership & Pricing: https://www.ecosystem.drgpcr.com/university-pricingWeekly News: https://www.ecosystem.drgpcr.com/gpcr-weekly-news | — | ||||||
| 5/6/26 |  The Beta-2 Agonist That Doesn't Stop Working — Tore Bengtsson | Every beta-2 agonist ever tested for muscle growth hits the same wall: desensitization. Dr. Tore Bengtsson built one that doesn't.A professor at Stockholm University and founder of Atrogi, Dr. Bengtsson has spent 25 years studying how beta-adrenergic receptors regulate metabolism, muscle, and brown fat. His lab developed 1,500+ compounds that activate beta-2 through distinct signaling pathways, and one is now heading into Phase 2 clinical trials. He shares how a "failed" experiment cracked the problem, why incretins only address half of metabolic disease problems, and what muscle loss after 50 means for drug discovery strategy.Key takeaways:Classical beta-2 agonists fail because desensitization shuts down the responseSelectively activating specific signaling pathways from one receptor can produce entirely different outcomesIncretins reduce energy intake — but the energy expenditure side remains wide openThe correlation between muscle mass and longevity is one of the most underserved areas in metabolic medicine🔗 Dr. GPCR Ecosystem: https://www.ecosystem.drgpcr.com/🎓 Membership & Pricing: https://www.ecosystem.drgpcr.com/university-pricing📰 Weekly News: https://www.ecosystem.drgpcr.com/gpcr-weekly-news | — | ||||||
| 4/29/26 |  One Molecule, Two Opioid Receptors - Joseph Kim | Dr. Joseph Kim solved cryo-EM structures of mu and kappa opioid receptors bound to the same small molecule — and found it does something different at each one.In this conversation, Dr. Kim walks through his transition from cryo-electron tomography to GPCR structural biology in Ashish Manglik's lab at UCSF, the strategy behind solving inactive-state receptor structures, and why his favorite GPCR — the galanin receptor — has resisted every small-molecule screen thrown at it.Key takeaways:How one molecule acts as an antagonist at mu and an inverse agonist at kappaWhy the galanin receptor's peptide binding mode blocks conventional drug discoveryWhat it takes to switch fields with no prior biochemistry trainingHow building tools on "vanilla" GPCRs prepares you for exotic targets🔬 Dr. GPCR Ecosystem: https://www.ecosystem.drgpcr.com/💰 Membership & Pricing: https://www.ecosystem.drgpcr.com/university-pricing📰 Weekly News: https://www.ecosystem.drgpcr.com/gpcr-weekly-news | — | ||||||
| 3/18/26 |  Can Simulations Predict GPCR Ligand Bias? | How does ligand binding at the extracellular pocket of a GPCR reshape signaling on the intracellular side?Biased agonism is often measured through pathway activation assays, but the structural origin of ligand bias remains difficult to trace. Can molecular simulations reveal the communication routes that link ligand binding to G protein or arrestin signaling?In this conversation, computational biologist Anita Niveda explores how molecular dynamics and network analysis can map allosteric communication within GPCRs—revealing how microscopic structural pathways relate to macroscopic signaling outcomes. From discovering bioinformatics as an undergraduate to developing computational methods for quantifying ligand bias, the discussion moves through the scientific thinking behind modeling receptor signaling, collaborations between academia and industry, and how computational tools are becoming predictive instruments in drug discovery.Key Topics in This EpisodeHow molecular dynamics simulations reveal communication pathways connecting ligand binding sites to G protein or arrestin interfacesWhy mapping allosteric communication networks helps explain biased agonism in GPCR signalingWhat computational strategies can quantify ligand bias directly from receptor structuresHow receptor subtype selectivity emerges from subtle structural and dynamic differences in binding pocketsWhy academic–industry collaborations can accelerate method development in receptor pharmacologyWhat career decisions shape the path from computational biology training to drug discovery rolesTimestamps0:00 A structural question behind ligand bias1:30 Introduction and scientific background3:40 Discovering bioinformatics and computational biology7:30 First encounters with GPCR structural biology9:40 Finding and choosing a postdoctoral lab16:40 Entering GPCR research and allosteric communication18:20 Quantifying ligand bias using simulations20:00 Mapping signaling pathways through receptor residues23:30 Academic–industry collaboration with Boehringer Ingelheim27:00 Moving from academia to industry research35:00 Interviewing and transitioning into biotech45:00 Aha moments in computational GPCR research50:00 The diversity of GPCR families and signaling biologyKeywords: GPCR podcast, GPCR signaling, biased agonism, drug discovery, receptor pharmacology | — | ||||||
| 3/4/26 |  Why Mosquitoes Hunt You: The GPCR Behind the Bite - Laura Duvall | Conserved neuropeptide Y GPCRs orchestrate both feeding and mating behaviors in mosquitoes, with direct translational parallels to human gut-brain signaling.Quick SummaryLearn how receptor internalization and neuropeptide GPCR signaling underlie the regulation of mosquito host-seeking and reproduction. Dr. Laura Duvall details the use of CRISPR-based assay development and fluorescence-driven phenotyping to connect molecular manipulation to whole-animal behavior. Her approach provides actionable insights for gpcr drug discovery and tools to dissect homologous pathways across model systems, with implications for pharmacology research targeting vector-borne disease transmission.Key TakeawaysNeuropeptide Y GPCRs modulate both host attraction and mating in Aedes aegypti.CRISPR and fluorescence assays enable precise behavioral phenotyping in vivo.GPCR-targeted compounds designed for humans can modulate mosquito receptors.NPY receptor expression in mosquito gut mirrors mammalian gut-brain signaling axes.Automated behavioral assays combined with machine learning sharpen data resolution and reduce human bias.Dr. GPCR Links & ResourcesExplore essential resources:Dr. GPCR EcosystemMembership & PricingWeekly NewsAdvance your research—discover the power of Dr. GPCR Premium.About the GuestDr. Laura Duvall earned her B.A. in Biochemistry and Biological Basis of Behavior from the University of Pennsylvania, followed by a PhD at Washington University in St. Louis, where she explored neuropeptide regulation of circadian behavior in Drosophila. Transitioning from fruit flies to mosquitoes, she pursued postdoctoral research at Rockefeller University with Leslie Vosshall, focusing on the molecular regulation of feeding and mating behaviors in Aedes aegypti. In 2019, she established her independent laboratory at Columbia University's Department of Biological Sciences and the Zuckerman Institute. Dr. Duvall’s work is recognized by awards including the Beckman Young Investigator Award, Klingenstein-Simons Fellowship in Neuroscience, and the Pew Scholars Program, reflecting her drive to unravel the complex signaling mechanisms that govern mosquito and broader animal behavior.Guest on The WebLinkedIn: https://www.linkedin.com/in/laura-duvall-28a03485/Google Scholar: https://scholar.google.com/citations?user=Vk3KGSoAAAAJ&hl=enLab: https://www.duvalllab.com/ | — | ||||||
| 2/18/26 | GPCR Location and Lipid Raft Signaling | Key TakeawaysHow does the precise localization of GPCRs in lipid rafts reshape drug discovery strategy? Examine implications for functional assays and therapeutic innovation.Explore the pivotal role of GPCR-lipid raft compartmentalization in receptor signaling, desensitization, and pharmacology research. Dr. Keyvan Sedaghat discusses assay approaches, regulatory mechanisms, and the translational impact of bitter taste receptors beyond sensory biology. Leveraging decades of experience in assay development and database creation, he offers actionable insights for researchers optimizing GPCR drug discovery pipelines.Compartmentalization of GPCRs in lipid rafts directly influences receptor signaling and drug response.Desensitization pathways of dopamine D1 receptors depend on precise phosphorylation domains—challenging classical paradigms.Bitter taste receptors demonstrate functional relevance in non-gustatory tissues with emerging therapeutic applications.Database-driven research accelerates the identification of receptor-microdomain interactions for novel targets.Integration of computational modeling and biochemical validation is essential for advancing GPCR assay strategies.Dr. GPCR Links & ResourcesAccess the Dr. GPCR Ecosystem at https://www.ecosystem.drgpcr.com/ for community, tools, and databases.Details on Membership & Pricing: https://www.ecosystem.drgpcr.com/university-pricingGPCR Weekly News: https://www.ecosystem.drgpcr.com/gpcr-weekly-newsExplore Dr. GPCR Premium for expanded translational resources and networking.About the GuestDr. Keyvan Sedaghat holds a pharmacy degree and a PhD in cellular and molecular medicine, specializing in pharmacology, from the University of Ottawa. With over two decades of academic experience, he has served as a professor, senior lecturer, and chief scientific officer in the pharmaceutical and cosmetic industries. Dr. Sedaghat’s work spans peer-reviewed publications and editorial roles across journals in molecular pharmacology, cell signaling, and G protein-coupled receptors. His scientific drive centers on unraveling molecular mechanisms underlying GPCR function and translating those findings into effective teaching, research, and drug discovery strategies.Guest on the Web:LinkedInGoogle Scholar | — | ||||||
| 2/4/26 | Choosing the Right GPCR Assays for Translational Drug Discovery 180 | Episode SummaryPotent in vitro hits often fail in vivo—Martin Marro details how robust assay choice and pathway deconvolution can revive GPCR drug discovery programs.Listeners will learn practical approaches to assay development for GPCR drug discovery, the pitfalls of calcium readouts, and how identifying pathway bias impacts translational success. Dr. Marro shares his experience bridging in vitro–in vivo gaps, refining selection flowcharts, and leveraging pharmacology research to drive clinical candidates. His strategic perspective is rooted in years of leading multimodal discovery teams in pharma and biotech. Key TakeawaysAssay selection critically shapes the trajectory from hit to clinic.Calcium and IP1 assays may not predict in vivo efficacy for all Gq-coupled receptor targetsAlternative pathway analysis may be essential for mechanism elucidation.Persistence in probing beyond standard readouts can rescue high-profile discovery programs. Team structure and collaborative problem-solving are pivotal in resolving translational bottlenecks.Explore Dr. GPCR Resources- Dr. GPCR Ecosystem- Membership & Pricing- Weekly NewsExplore the full depth of GPCR resources, events, and member-exclusive tools with Dr. GPCR Premium.About the GuestDr. Martin Marro leads the Cell Pharmacology group in the DOCTA division at Lilly’s Seaport Innovation Center in Boston, MA. Trained as a pharmacologist, Dr. Marro has accumulated over 20 years of experience spanning large pharmaceutical firms—including GSK, Novartis, and Lilly—and innovative biotech such as Tectonic Therapeutic. He holds deep expertise in early drug discovery across small molecules, peptides, and antibody therapeutics for metabolic, cardiovascular, and gastrointestinal diseases.Dr. Marro’s research has been central to the discovery and characterization of multiple clinical candidates, with a focus on GPCR target validation, receptor pharmacology, and translational assay strategies. He played a key role in patenting and developing novel fatty acid-conjugated GLP-1 receptor agonists. Driven by the challenge of translating robust in vitro science into clinical proof-of-concept, Dr. Marro’s leadership continues to impact the field of GPCR drug discovery.Keywords: gpcr podcast, assay development, pharmacology research. | — | ||||||
| 12/17/25 | How Academia–Industry Collaboration Is Scaling GLP-1 Receptor Tools | Dr. GPCR Podcast #179 | GPCR tools don’t move the field forward unless researchers can actually use them. This episode breaks down how collaboration turns probes into progress.SummaryIn the final episode of this series, David Hodson, Johannes Broichhagen, and Maria Majellaro unpack how academic labs and Celtarys Research partnered to scale fluorescent probes, improve assay development, and support gpcr drug discovery. The conversation spans receptor internalization, fluorescence assays, tech transfer realities, and why tool availability—not just invention—drives translational pharmacology research.Key takeawaysWhy accessibility defines the real impact of GPCR toolsHow industry enables scalable assay developmentLessons from receptor internalization studies in complex tissuesWhat makes academia–industry collaborations actually workRead more here: https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/scaling-glp-1-receptor-tools-through-academia–industry-collaboration | — | ||||||
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 12/3/25 | Imaging GPCRs in Action: Chemical Probes for Next-Level Discovery | Dr. Johannes Broichhagen #178 | Chemical probes are reshaping how we map GLP-1R in real time — revealing receptor pools antibodies can’t reliably capture.This is Episode 2 of a 3-part GPCR tool-development series created in partnership with Celtarys Research.Summary:Dr. Johannes Broichhagen aka JB breaks down the design logic behind fluorophore-linked peptides, assay trade-offs, and what true receptor internalization looks like in live tissue. A concise masterclass in assay development and GPCR drug discovery.What you’ll learn:• Why antibody variability pushed JB toward chemical probe engineering• The design logic behind Luxendin-based fluorescent tools — and how structure guides function • What “good assay development” looks like when cells, tissue, and probe behavior collide• Behind-the-scenes stories from the collaboration with David Hodson• Why parallelized experiments matter for reproducibility and signal quality• How small-molecule probes outperform antibodies in live-cell and tissue imaging• The surprising breakthroughs that shifted JB’s entire research trajectory• Future directions: multi-color GPCR mapping, AI-guided ligand design, and in vivo chemical biology Dr GPCR Links & Resources:• Dr. GPCR Ecosystem: https://www.ecosystem.drgpcr.com/ • Membership & Pricing: https://www.ecosystem.drgpcr.com/university-pricing• Weekly News: https://www.ecosystem.drgpcr.com/gpcr-weekly-news | — | ||||||
| 11/19/25 | Mapping GLP-1 & GIP Receptors in Metabolic Disease with Dr. David Hodson - Episode 177 | Precise receptor mapping is reshaping how we understand incretin biology. David Hodson explains how GPCR-targeted chemical probes reveal where GLP-1 and GIP receptors actually signal across pancreas and brain—and what this means for metabolic drug design.Learn how these tools refine gpcr drug discovery, clarify receptor internalization, and guide next-gen therapeutics.🎓 Join Dr. GPCR Premium for exclusive episodes + research tools → https://www.ecosystem.drgpcr.com/ | — | ||||||
| 11/12/25 | Inside Monash: Organized Signaling, Real Impact | What makes Monash a model for modern pharmacology? Dr. Michelle Halls reveals how collaboration, mentorship, and receptor organization shape today’s GPCR breakthroughs — from femtomolar signaling to cancer biology. A look inside a lab culture built on precision, openness, and impact.👉 Watch the complete episode: https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/leadership-luck-and-gpcr-signaling🎓 Join Dr. GPCR Premium for exclusive episodes + research tools → https://www.drgpcr.com/premium | — | ||||||
| 10/22/25 |  Model. Predict. Discover. with Dr. Jens Carlsson | Dr. GPCR Podcast #175 | Predicting, not just explaining, can change how we design GPCR-targeted drugs. Jens Carlsson reveals how modeling bridges structure, function, and pharmacology.Hear how predictive simulations shape assay development, GPCR drug discovery, and collaborations across disciplines.🎓 Join Dr. GPCR Premium for exclusive episodes + research tools → https://www.ecosystem.drgpcr.com/gpcr-university-pricing Watch the complete episode at https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/model-predict-discover | — | ||||||
| 9/22/25 |  From Rare Earth Probes to Internalization Assays: The pHSense Story with Dr. Eric Trinquet from Revvity | Dr. GPCR Podcast #174 | 🔬 What if you could track GPCR internalization—no wash, high-throughput, and in endogenous systems?Discover how Dr. Eric Trinquet and Revvity built pH Sense, a next-gen fluorescence assay that redefines receptor internalization workflows. Learn assay trade-offs, tool design, and how to decode GPCR behavior with precision.🎓 Join Dr. GPCR Premium for exclusive episodes + research tools → https://www.ecosystem.drgpcr.com/gpcr-university-pricingWatch the complete episode at https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/from-rare-earth-probes-to-real-internalization-assays-the-ph-sense-story | — | ||||||
| 9/2/25 |  From Curiosity to Breakthrough: Ajay Yekkirala on GPCR Innovation | Dr. GPCR Podcast #173 | What if a failed med school plan led to a biotech breakthrough?Ajay Yekkirala shares how GPCRs, AI, and scientific curiosity are reshaping pain therapeutics — and what it really takes to build better medicines.Watch the video version of this podcast episode: What if a failed med school plan led to a biotech breakthrough?Ajay Yekkirala shares how GPCRs, AI, and scientific curiosity are reshaping pain therapeutics — and what it really takes to build better medicines.Watch the video version of this podcast episode: https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/from-curiosity-to-breakthrough-ajay-yekkirala-on-gpcr-innovation | — | ||||||
| 8/19/25 |  Xylazine, Fentanyl, and the Fight for Breath with Catherine Demery | When fentanyl slows your breath and xylazine traps it, the clock starts ticking.PhD candidate Catherine Demery takes us inside her fight to understand how fentanyl and xylazine shut down breathing in different ways—work that blends GPCR pharmacology, animal models, and real-time street data to combat the opioid crisis.Watch the video version of this podcast episode: Ep 172 with Catherine Demery | — | ||||||
| 8/5/25 |  Smells Like GPCR Spirit: Cracking Olfactory Codes with Alessandro Nicoli / Dr. GPCR Podcast #171 | Watch the video version of this podcast episode.https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-171-with-alessandro-nicoli---------------------------------Become a #DrGPCR Ecosystem Member---------------------------------Imagine a world in which the vast majority of us are healthy.The #DrGPCR Ecosystem is all about dynamic interactions between us working towards exploiting the druggability of #GPCRs. We aspire to provide opportunities to connect, share, form trusting partnerships, grow, and thrive together.---------------------------------To build our #GPCR Ecosystem, we created various enabling outlets.Premium YearlyPremium Yearly for TeamsDeveloping CountriesAre you a #GPCR professional?Subscribe to the Classified GPCR Weekly NewsListen and subscribe to #DrGPCRPodcast | — | ||||||
| 7/22/25 |  GPCRs and the Science Behind Pain & Recovery with Dr. Alex Serafini / Dr. GPCR Podcast #170 | Watch the video version of this podcast episode.https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-170-with-dr-alex-serafini---------------------------------Become a #DrGPCR Ecosystem Member---------------------------------Imagine a world in which the vast majority of us are healthy.The #DrGPCR Ecosystem is all about dynamic interactions between us working towards exploiting the druggability of #GPCRs. We aspire to provide opportunities to connect, share, form trusting partnerships, grow, and thrive together.---------------------------------To build our #GPCR Ecosystem, we created various enabling outlets.Premium YearlyPremium Yearly for TeamsDeveloping CountriesAre you a #GPCR professional?Subscribe to the Classified GPCR Weekly NewsListen and subscribe to #DrGPCRPodcast | — | ||||||
| 7/8/25 |  GPCR Pharmacology, Career Twists & Serendipity with Dr. Sokhom Pin / Dr. GPCR Podcast #169 | Watch the video version of this podcast episode.https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-169-with-dr-sokhom-pin---------------------------------Become a #DrGPCR Ecosystem Member---------------------------------Imagine a world in which the vast majority of us are healthy.The #DrGPCR Ecosystem is all about dynamic interactions between us working towards exploiting the druggability of #GPCRs. We aspire to provide opportunities to connect, share, form trusting partnerships, grow, and thrive together.---------------------------------To build our #GPCR Ecosystem, we created various enabling outlets.Premium YearlyPremium Yearly for TeamsDeveloping CountriesAre you a #GPCR professional?Subscribe to the Classified GPCR Weekly NewsListen and subscribe to #DrGPCRPodcast | — | ||||||
| 6/10/25 |  Baking Molecules, Building Probes: When Chemists Think Like Biologists with Dr. Maria Majellaro / Dr. GPCR Podcast 168 | Watch the video version of this podcast episode:https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-168-with-dr.-maria-majellaro-from-celtarysVisit Celtarys' website in the Ecosystem: https://www.ecosystem.drgpcr.com/celtarys-research-dr-gpcr-ecosystemRead the DrGPCR x Celtarys Partnership Press Release: https://www.ecosystem.drgpcr.com/post/dr-gpcr-and-celtarys-research-join-forces-to-expand-access-to-innovative-gpcr-toolsLearn more about Celtarys Research: https://www.celtarys.com/---------------------------------Become a #DrGPCR Ecosystem Member---------------------------------Imagine a world in which the vast majority of us are healthy.The #DrGPCR Ecosystem is all about dynamic interactions between us working towards exploiting the druggability of #GPCRs. We aspire to provide opportunities to connect, share, form trusting partnerships, grow, and thrive together.---------------------------------To build our #GPCR Ecosystem, we created various enabling outlets.Premium YearlyPremium Yearly for TeamsDeveloping CountriesAre you a #GPCR professional?Subscribe to the Classified GPCR Weekly NewsListen and subscribe to #DrGPCRPodcast | — | ||||||
| 5/27/25 |  Hacking GPCRs: Tools, Tech & Drug Discovery w/ Drs. Tom Sakmar & Ilana Kotliar / Dr.GPCR Podcast 167 | Watch the video version of this podcast episode.https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-167-with-tom-sakmar-%26-ilana-kotliar---------------------------------Become a #DrGPCR Ecosystem Member---------------------------------Imagine a world in which the vast majority of us are healthy.The #DrGPCR Ecosystem is all about dynamic interactions between us working towards exploiting the druggability of #GPCRs. We aspire to provide opportunities to connect, share, form trusting partnerships, grow, and thrive together.---------------------------------To build our #GPCR Ecosystem, we created various enabling outlets.Premium YearlyPremium Yearly for TeamsDeveloping CountriesAre you a #GPCR professional?Subscribe to the Classified GPCR Weekly NewsListen and subscribe to #DrGPCRPodcast | — | ||||||
| 5/13/25 |  When to Walk, When to Run: Lessons from the GPCR Trenches with Dr. Ben Clements / Dr.GPCR Podcast 166 | Episode 166 of the Dr. GPCR Podcast features Benjamin Clements, a postdoctoral fellow at the University of Michigan, who brings fresh insight into the therapeutic promise of GPCRs — particularly in the context of opioid pharmacology. With a background in pharmaceutical sciences and neuroscience, Ben now focuses on positive allosteric modulators (PAMs) targeting the mu-opioid receptor, aiming to preserve opioid analgesia while reducing harmful side effects like respiratory depression and addiction.In this episode, Ben and Dr. Yamina Berchiche discuss how a passion for translational science led him to investigate chronic pain models, including neuromas, where opioids traditionally fail. His lab’s preliminary findings — including a tenfold improvement in methadone efficacy — highlight the potential of GPCR-targeted allosteric modulators to change the treatment landscape for intractable pain conditions. These discoveries are the result of collaborative, curiosity-driven science in a lab culture that values both rigor and levity.Ben also shares his perspective on learning “old-school” assays like radioligand binding and GTPγS, emphasizing their enduring value even amid advanced high-throughput techniques. The conversation touches on mentorship, imposter syndrome, and the critical importance of creating space for new voices in the GPCR field. As Ben puts it:“Academia is all about knowing when to walk and when to run.”This episode is a powerful reminder of the role that early-career scientists play in shaping the future of GPCR drug discovery — blending pharmacological fundamentals with bold experimentation and a deep commitment to patient-centered science.Watch the complete episode at: https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-166-with-ben-clements---------------------------------Become a #DrGPCR Ecosystem Member---------------------------------Imagine a world in which the vast majority of us are healthy.The #DrGPCR Ecosystem is all about dynamic interactions between us working towards exploiting the druggability of #GPCRs. We aspire to provide opportunities to connect, share, form trusting partnerships, grow, and thrive together.---------------------------------To build our #GPCR Ecosystem, we created various enabling outlets.Premium YearlyPremium Yearly for TeamsDeveloping CountriesAre you a #GPCR professional?Subscribe to the Classified GPCR Weekly NewsListen and subscribe to #DrGPCRPodcast | — | ||||||
| 4/29/25 |  Finance is Science too with Chuck DeWeese & Joe St. Germain / Dr.GPCR Podcast 165 | In this episode of the Dr. GPCR Podcast, we step outside the lab to talk about what keeps research-driven organizations running behind the scenes: finance and operations. Yamina Berchiche is joined by Joe St. Germain and Chuck DeWeese from Company Launch Partners to discuss the real-world challenges of building startups and nonprofits—including Dr. GPCR itself. Joe shares his leap from corporate finance to launching a firm that supports early-stage ventures, while Chuck explains his journey from sales to becoming the behind-the-scenes problem-solver for mission-driven organizations.What emerges is a compelling conversation about how science and finance are more similar than we think. Chuck and Joe explain how reconciling financial data mirrors the satisfaction of solving scientific puzzles. They also dive into the unique hurdles of accounting for grants, setting up sustainable financial systems, and choosing clients whose values align with their own. The episode bridges two traditionally separate worlds—science and business—by highlighting their shared reliance on structure, integrity, and impact.At its core, the episode is about building things that last—with the right people. From hiring based on character and teachability to growing teams organically through trust and mentorship, Joe and Chuck share lessons that resonate far beyond finance. Whether you’re a GPCR scientist applying for a grant or a founder navigating early growth, this conversation is a powerful reminder that success is never solo—it’s built on relationships, purpose, and a clear sense of mission.Watch the complete episode at: https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-165-with-chuckdeweese-joestgermain | — | ||||||
| 4/15/25 |  Signals, pH, and Discovery: Cracking GPCR Mysteries with Dr. Ian Chronis / Dr.GPCR Podcast 164 | In this science-focused episode of the Dr. GPCR podcast, we meet Dr. Ian Chronis, a freshly minted PhD from the University of Michigan. While his academic roots started in classical history and ancient Greek, Ian’s curiosity pulled him toward chemistry, then pharmacology, and eventually into the complex world of GPCR signaling. His story is a testament to the power of staying open to change and following emerging scientific questions wherever they lead.Ian’s doctoral work focused on two key GPCR systems: the well-characterized β2-adrenergic receptor and the lesser-known proton-sensing receptor GPR65. In the former, he explored how PKA phosphorylation modulates receptor interactions and discovered a regulatory role for 14-3-3 proteins. But it’s GPR65 — a receptor that constitutively internalizes and signals from acidic endosomes — that has captured Ian’s attention and become the centerpiece of his current research. Unlike classical GPCRs, GPR65 uses non-canonical internalization mechanisms, presenting new opportunities to uncover novel biology.The receptor’s ability to signal within the tumor microenvironment and immune cells makes it an emerging drug target, especially in cancer immunotherapy. However, there are still major gaps: no selective ligands, little clarity on its internalization machinery, and limited tools to modulate its function. Ian’s wish list? A high-affinity agonist and antagonist to begin untangling these questions. Until then, he's carefully optimizing pH-based assays and preparing for next steps in a postdoctoral lab focused on more physiological and therapeutic systems.Whether he’s decoding novel trafficking pathways or reflecting on career strategy, Ian brings a balanced perspective that’s both ambitious and grounded. His advice to peers? Attend talks outside your field, learn constantly, and surround yourself with people who make science sustainable. This episode is a must-listen for those navigating the intersection of curiosity, technical rigor, and translational potential in the GPCR research community.Watch the video version of this podcast episode:https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-164-with-dr.-ian-chronis---------------------------------Become a #DrGPCR Ecosystem Member---------------------------------Imagine a world in which the vast majority of us are healthy.The #DrGPCR Ecosystem is all about dynamic interactions between us working towards exploiting the druggability of #GPCRs. We aspire to provide opportunities to connect, share, form trusting partnerships, grow, and thrive together.---------------------------------To build our #GPCR Ecosystem, we created various enabling outlets.Premium YearlyPremium Yearly for TeamsDeveloping CountriesAre you a #GPCR professional?Subscribe to the Classified GPCR Weekly NewsListen and subscribe to #DrGPCRPodcast | — | ||||||
Showing 25 of 145
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.
Similar Audience Demographics
Podcasts that attract a similar listener profile
Chart Positions
9 placements across 9 markets.
Chart Positions
9 placements across 9 markets.